Displaying 361 - 380 of 1516
UnitedHealth Group and DaVita; Analysis of Agreement Containing Consent Orders To Aid Public Comment
Joint Statement of Commissioners Phillips and Wilson Concerning UnitedHealth Group and DaVita
Joint Statement of Commissioners Rohit Chopra and Rebecca Kelly Slaughter Concerning UnitedHealth Group and DaVita
FTC Imposes Conditions on UnitedHealth Group’s Proposed Acquisition of DaVita Medical Group
FTC to Hold Workshop Tomorrow Regarding the Impact of Certificates of Public Advantage
FTC Announces Agenda for June 18 Workshop, A Health Check on COPAs
FTC Submits Comment on Proposed Information Blocking Rule to the Department of Health & Human Services Office of the National Coordinator for Health Information Technology (ONC)
FTC Staff Comment Before the Department of Health and Human Services Regarding the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program
FTC Staff Comment to the FDA Department of Health and Human Services on Its Updated Guidance for Industry on the “Nonproprietary Naming of Biological Products”
FTC Submits Comment on FDA Guidance Regarding Nonproprietary Naming of Biological Products
Administrative Law Judge Upholds FTC’s Complaint Challenging Consummated Merger of Companies that Make Microprocessor Prosthetic Knees
FTC Charges Surescripts with Illegal Monopolization of E-Prescription Markets
FTC to Hold Workshop on Certificates of Public Advantage in Healthcare Markets
FTC Approves Final Order Imposing Conditions on Merger of Fresenius Medical Care AG & KGaA and NxStage Medical, Inc.
Fresenius Medical Care and NxStage Medical, In the Matter of
The FTC required healthcare companies Fresenius Medical Care AG & KGaA and NxStage Medical, Inc. to divest all rights and assets related to NxStage’s bloodline tubing set business to B. Braun Medical, Inc. as part of a settlement resolving charges that Fresenius’s proposed $2 billion acquisition of NxStage likely would be anticompetitive. The FTC’s complaint alleges that the proposed merger would harm competition in the U.S. market for bloodline tubing sets that are compatible with hemodialysis machines used in clinics that treat chronic renal failure. Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments. Fresenius and NxStage are two of only three significant suppliers of bloodline tubing sets used in open architecture hemodialysis machines in the United States. Fresenius and NxStage together control 82 percent of the market for bloodlines.The settlement requires Fresenius and NxStage to divest to B. Braun all assets and rights to research, develop, manufacture, market, and sell NxStage’s bloodline tubing sets.
FTC Concludes that Impax Entered into Illegal Pay-for-Delay Agreement
Displaying 361 - 380 of 1516